

TEASER

3



GLOBAL EXPERT SUMMIT ON HYPOPARATHYROIDISM

ASSESSING AND MANAGING A COMPLEX DISEASE

The journey of the patient with
hypoparathyroidism: Burden of illness

Prof. Andrea Giustina

20th–21st Nov, 2020

Code: VV-MEDMAT-2431 – Date of preparation: August 2020

This meeting is initiated, organized and funded by Takeda. This event is for healthcare professionals only.

Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

Copyright © 2020 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited.

Transcript

Hello and Welcome!

My name is **Andrea Giustina**.

I'm an endocrinologist from Milan in Italy and I would like to briefly preview the exciting work we will discuss on November 21st during the third session of this year's virtual Global Expert Summit on Hypoparathyroidism (GESH).

Notes/slides



Andrea Giustina

Professor of Endocrinology and Metabolism,
Department of Endocrinology,
San Raffaele Vita-Salute University and
IRCCS San Raffaele Hospital
Milan, Italy

Transcript

The session will focus on the burden of hypoparathyroidism for both patients and caregivers and how it changes over the course of the patient's journey.

As you know, hypoparathyroidism results in a wide range of symptoms and their impacts contribute to decreased quality of life for patients with this disease.


My colleague, **Prof Heide Siggelkow**, will review recent work that has evaluated the effects of hypoparathyroidism on quality of life.

Notes/slides



Heide Siggelkow

Impact of Hypoparathyroidism on HRQoL
SF-36 reported outcomes across domains






Transcript

Hypoparathyroidism is also associated with increased morbidity and these data will be reviewed by **Prof. Tanja Sikjaer**.

Notes/slides



Tanja Sikjaer

	 Renal Disease	 CVD	 Infections
Too low calcium levels		↑	
"High" phosphate levels / high Ca x P product	↑		↑
Episodes of hypercalcemia	↑	↑	↑
Long disease duration	↑	↑	↑

Transcript

Last but not least, hypoparathyroidism is associated with an increased risk for infection although the reason for this is not clear.

Prof. Mary Anna Venneri and **Prof. Andrea Isidori** will outline the most recent investigations in this field.

And finally, I will extend the discussion by summarizing guidance from the European Society of Endocrinology regarding the Covid-19 pandemic.


Notes/slides



Mary Anna
Venneri



Andrea
Isidori





Transcript

These presentations will be followed by several “rapid fire” case studies focused on nephrolithiasis, diabetes, and pregnancy & lactation in hypoparathyroidism.

Notes/slides





**Markus
Ketteler**



**Nicola
Napoli**



**Sigríður
Björnsdóttir**



TEASER

3

The journey of the patient with hypoparathyroidism: Burden of illness



Transcript

As you can see, this 3rd session focusing on the patient journey with hypoparathyroidism and the burden of the illness promises to be very dynamic with a lot of medical experts engaging with us!

Do not miss it!

Save the date as we all look forward to our interaction on November 21st!

Notes/slides



TEASER 3



GLOBAL EXPERT SUMMIT ON HYPOPARATHYROIDISM

ASSESSING AND MANAGING A COMPLEX DISEASE

The journey of the patient with
hypoparathyroidism: Burden of illness

20, 21
Nov

Save the date!

Code: VV-MEDMAT-2431 – Date of preparation: August 2020
This meeting is initiated, organized and funded by Takeda. This event is for healthcare professionals only.
Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).
Copyright © 2020 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited.

TEASER

3



GLOBAL EXPERT SUMMIT ON HYPOPARATHYROIDISM

ASSESSING AND MANAGING A COMPLEX DISEASE

The journey of the patient with
hypoparathyroidism: Burden of illness

20, 21
Nov

Save the date!

Code: VV-MEDMAT-2431 – Date of preparation: August 2020

This meeting is initiated, organized and funded by Takeda. This event is for healthcare professionals only.

Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

Copyright © 2020 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited.